<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00186056</url>
  </required_header>
  <id_info>
    <org_study_id>78804</org_study_id>
    <nct_id>NCT00186056</nct_id>
  </id_info>
  <brief_title>Mifepristone in Refractory Depression</brief_title>
  <official_title>Mifepristone in Refractory Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to examine the effectiveness of mifepristone treatment in
      patients with refractory depression. Refractory depression is defined as clinical depression
      that is unimproved after treatment with at least 2 different antidepressants of adequate dose
      and time trial. Mifepristone will augment current medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Procedures:

      This study will be a double-blind placebo-controlled 5-week trial.

      Thirty patients with treatment refractory major depression will be studied over a one year
      period. Patients will be screened for eligibility, no more than two weeks prior to
      enrollment, which will involve psychiatric interviews (including the SCID-Mini, HAM-D, BPRS,
      and CGI-S), a physical exam, and blood and urine analyses.

      Clinical laboratory assessments include a serum pregnancy test (for all females),
      comprehensive blood count, comprehensive metabolic panel, lipid panel, fasting insulin,
      glucose tolerance test, urine toxicology, and electrocardiogram.

      If subjects are found to be eligible, they will be asked return within two weeks of their
      eligibility screening visit to begin the study. Additionally, they will be asked to keep a
      diary of their sleep pattern for 1 week prior to entering the study and for the entire 5 week
      duration of the study.

      On the day before beginning study medication (Study Day 0), patients will be administered the
      HAM-D, BPRS, CGI-S, CGI-I and neuropsychological tests, and vitals will be obtained. Patients
      will also undergo an afternoon blood draw, with a blood sample taken each hour beginning at
      1:00PM and ending at 4:00PM, in order to assess baseline cortisol levels. Patients will then
      be given a 4-day supply of double-blind study medication (either 24 100mg mifepristone
      tablets or 24 placebo tablets) with instructions to self-administer 6 tablets each morning.

      Patients will return on Day 4 to have study staff check on medication adherence, take vitals,
      and assess any possible adverse events. Patients will then receive an additional 3-day supply
      of double-blind study medication (either 18 100mg mifepristone tablets or 18 placebo tablets
      with instructions to orally self-administer 3 tablets each morning.

      Patients will return on Day 7 to have study staff check on medication adherence, take vitals,
      and assess any possible adverse events. Patients will also repeat clinical laboratory
      assessments (including a serum pregnancy test for all females, comprehensive blood count,
      comprehensive metabolic panel, lipid panel, fasting insulin, glucose tolerance test, and
      urinary analysis) and ECG, and repeat the afternoon blood draw from 1:00PM to 4:00PM to
      assess cortisol levels. They will also be administered the HAM-D, BPRS, CGI-S, and CGI-I.

      Patients will return after one week (Day 14) for administration of the HAM-D, BPRS, CGI-S,
      CGI-I, and assessment of any possible adverse events, and vitals. Patients will also repeat
      the afternoon blood draw from 1:00PM to 4:00PM to assess cortisol levels.

      Patients will also return on Day 28 and Day 35 for administration of the HAM-D, BPRS, CGI-S,
      CGI-I, and assessment of any possible adverse events, and vitals. All female patients will
      undergo serum pregnancy testing on Day 35. In addition, all patients will be asked turn in
      their sleep diary to the research staff and will receive a neuropsychological test on day 35.

      During the study, patients will be monitored for adrenal insufficiency and signs of
      Cushingnoid effects by monitoring blood pressure, pre-treatment (eligibility) and
      post-treatment (Day 7) metabolic panels (including measures of glucose and potassium), and
      monitoring of any changes that occur during the study.

      Women with child-bearing potential are required to use a double-barrier method to prevent
      pregnancy during the study and for 30 days after the study. The double-barrier method
      includes 2 of the following methods of contraception: spermicidal foam, condom diaphragm, or
      IUD. Women of child-bearing potential are defined as women, 18 years of age or older, who
      have not been diagnosed by their primary care physician or gynecologist with menopause, and
      who have an intact uterus. Women not of child-bearing potential are defined as women, 18
      years of age or older, who are status post hysterectomy or have been diagnosed by their
      primary care physician or gynecologist with menopause (as clinically defined by examination
      and results of FSH/LH blood work).

      After the study, subjects will be referred for follow-up care as needed.

      Subjects will not be paid for their participation in this protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale</measure>
    <time_frame>Baseline and Day 35 HAMD scores</time_frame>
    <description>Hamilton Depression Rating Scale. Minimum score of 0 (no depressive symptoms) to maximum of 68 (very severely depressed).
Outcome Measure is reporting a Change from Baseline in HAMD scores, i.e., scores at Day 35 minus scores at Baseline.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Mifepristone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received mifepristone for 6 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients received placebo for 6 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>Glucocorticoid antagonist</description>
    <arm_group_label>Mifepristone</arm_group_label>
    <other_name>RU 486</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Inactive placebo tab</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria::

          -  21-item HAM-D score of 20 or above.

          -  If currently taking antipsychotic, antidepressant, anticonvulsant, and/or
             mood-stabilizing medications, must be stable on the medication for at least three
             weeks prior to entering the study.

          -  At least 2 failed antidepressant medication trials of adequate dose and duration.

          -  Between 18 and 75 years of age.

          -  Not currently pregnant or trying to become pregnant.

        Exclusion Criteria:-History of schizophrenia or other psychotic disorders.

          -  Transcranial magnetic stimulation treatment or ECT in the 3 months prior to starting
             the study.

          -  History of vagus nerve stimulation treatment.

          -  No unstable or untreated cardiovascular disease, hypertension, or endocrine disorder.

          -  Current use of oral contraceptives or any other drug that may result in adverse
             drug-mifepristone interactions effects (including Amiodarone, Clarithromycin,
             Erythromycin, Fluconazole, Fluvoxamine, Indinavir, Intraconazole, Ketoconazole,
             Metronidazole, Miconazole, Nefazodone, Nelfinavir, Norfloxacin, Omeprazole, Quinine,
             Ritonavir, Saquinavir, Troleandomycin, Zafirlukast, Carbamazepine, Dexamethasone,
             Ethosuximide, Phenobarbital, Phenytoin, Primidone, Rifabutin, Rifampin, Troglitazone).
             A 30-day wash-out period for oral contraceptives is required before mifepristone
             begins.

          -  Previous allergic reaction to mifepristone or drugs of similar chemical structure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugh Brent Solvason</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>October 13, 2016</results_first_submitted>
  <results_first_submitted_qc>February 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 5, 2017</results_first_posted>
  <last_update_submitted>February 17, 2017</last_update_submitted>
  <last_update_submitted_qc>February 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Hugh Brent Solvason</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mifepristone</title>
          <description>Patients received mifepristone for 6 days
Mifepristone: Glucocorticoid antagonist</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients received placebo for 6 days
Mifepristone: Glucocorticoid antagonist</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mifepristone</title>
          <description>Patients received mifepristone for 6 days
Mifepristone: Glucocorticoid antagonist</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients received placebo for 6 days
Mifepristone: Glucocorticoid antagonist</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.92" spread="9.4"/>
                    <measurement group_id="B2" value="51.82" spread="9.6"/>
                    <measurement group_id="B3" value="51.43" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Depression Rating Scale</title>
        <description>Hamilton Depression Rating Scale. Minimum score of 0 (no depressive symptoms) to maximum of 68 (very severely depressed).
Outcome Measure is reporting a Change from Baseline in HAMD scores, i.e., scores at Day 35 minus scores at Baseline.</description>
        <time_frame>Baseline and Day 35 HAMD scores</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mifepristone</title>
            <description>Patients received mifepristone for 6 days
Mifepristone: Glucocorticoid antagonist</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients received placebo for 6 days
Mifepristone: Glucocorticoid antagonist</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Rating Scale</title>
          <description>Hamilton Depression Rating Scale. Minimum score of 0 (no depressive symptoms) to maximum of 68 (very severely depressed).
Outcome Measure is reporting a Change from Baseline in HAMD scores, i.e., scores at Day 35 minus scores at Baseline.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.75" spread="9.1"/>
                    <measurement group_id="O2" value="19.68" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.26</p_value>
            <method>ANOVA</method>
            <method_desc>Interaction of HAMD * medication group F(2,26)=1.38, eta sq = .05</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mifepristone</title>
          <description>Patients received mifepristone for 6 days
Mifepristone: Glucocorticoid antagonist</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients received placebo for 6 days
Mifepristone: Glucocorticoid antagonist</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brent Solvason</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-723-8331</phone>
      <email>solvason@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

